Carregant...
Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship
BACKGROUND: For many molecularly targeted agents, the probability of response may be assumed to either increase or increase and then plateau in the tested dose range. Therefore, identifying the maximum effective dose, defined as the lowest dose that achieves a pre-specified target response and beyon...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4119476/ https://ncbi.nlm.nih.gov/pubmed/25074481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2288-14-95 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|